Vertex Pharmaceuticals | VRTX - Trade Debtors



Vertex Pharmaceuticals reported $1.89B in Trade Debtors for its fiscal quarter ending in June of 2025.


Trade Debtors Change Date
AbbVie USD 12.48B 1.56B Mar/2025
Acadia Pharmaceuticals USD 119.69M 5.97M Jun/2025
Agios Pharmaceuticals USD 4.99M 1.64M Jun/2025
Alnylam Pharmaceuticals USD 567.11M 149.08M Jun/2025
Amgen USD 8.7B 569M Jun/2025
Arrowhead Research USD 9.7M 7.33M Jun/2025
Biogen USD 2.08B 87.5M Jun/2025
BioMarin Pharmaceutical USD 855.85M 116.68M Jun/2025
Bristol-Myers Squibb USD 15.1B 515M Jun/2025
Gilead Sciences USD 4.78B 393M Jun/2025
Incyte USD 842.89M 19.76M Jun/2025
Insmed USD 55.03M 7.29M Jun/2025
Ionis Pharmaceuticals USD 52.58M 12.87M Jun/2025
J&J USD 16.02B 1.18B Mar/2025
Merck USD 12.72B 1.14B Jun/2025
Moderna USD 457M 151M Jun/2025
Neurocrine Biosciences USD 595.7M 79.7M Jun/2025
Novartis USD 9.18B 451M Jun/2025
Pfizer USD 16.09B 1.35B Jun/2025
PTC Therapeutics USD 196.13M 14.36M Jun/2025
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Roche Holding CHF 13.46B 984M Dec/2024
Sanofi 8.21B 7.76B Jun/2025
Sarepta Therapeutics USD 609.6M 114.93M Jun/2025
Ultragenyx Pharmaceutical USD 124.46M 25.62M Jun/2025
United Therapeutics USD 379.3M 57.3M Jun/2025
Vertex Pharmaceuticals USD 1.89B 88.4M Jun/2025